The Food and Drug Administration on Monday approved Melinta Therapeutics' antibiotic Baxdela.
Baxdela is intended to treat skin and skin structure infections caused by various gram-positive and gram-negative bacteria, including methicillin-resistant Staphylococcus aureus. The antibiotic is available in intravenous and oral form.
"Antibiotic resistance is a growing concern, and physicians need more tools in the fight against this threat to modern medicine," said David Hooper, MD, professor of medicine at Cambridge, Mass.-based Harvard University and infection control leader at Massachusetts General Hospital in Boston. "Approval of new therapies like Baxdela … provides physicians another option in addressing the challenges of [acute bacterial skin and skin structure infections] patients."
More articles on supply chain:
25 top supply chains in 2017, as ranked by Gartner
Baltimore's naloxone supply dwindling as opioid overdose rates surge
Patients seeking financial assistance for $750k Biogen drug must sign away PHI